Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He has played a significant role in the creation, early sourcing, financing, and development of more than 100 companies, including over 39 which have reached valuations exceeding $1 billion. Mr. Nelsen is focused on generating new ideas for disruptive technologies or business models and partnering with founding management teams and entrepreneurs to execute on these visions by advancing novel platform technologies with the overarching goal of improving health care and outcomes. Recent successes include founding National Resilience to transform pharma manufacturing in the U.S., Vir Biotechnology’s COVID-19 antibody therapy, IPOS for Prime Medicine, Beam Therapeutics and Sana Biotechnology. Notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), Juno Therapeutics (sold to Celgene for $11.9 billion) and GRAIL (Sold to Illumina for $10 billion). Other prominent biotechnology and life sciences company investments include Array BioPharma (sold to Pfizer for $11.4 billion), Receptos (sold to Celgene for $7.2 billion), Sage Therapeutics (SAGE), Denali Therapeutics (DNLI), Karuna Therapeutics (KRTX), BEAM, Prime Medicine, Lyell Immunopharma, Editas (EDIT), Agios Pharmaceuticals (AGIO), Ikaria, deCODE Genetics (sold to Amgen), 10x Genomics, and Semma Therapeutics (sold to Vertex Pharmaceuticals), among others. Mr. Nelsen is a director of VIR, SANA, National Resilience, Lyell Immunopharma, and serves as Chairman of Hua Medicine, among others. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.